Last Friday, the National Comprehensive Cancer Cancer Network (NCCN) introduced a new way for doctors and patients to be able to consider the clinical “value” of treatment with specific drugs in specific forms of cancer. How useful this method is will take a while to work out. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: affordability, efficacy, evidence, guideline, NCCN, safety, value | Leave a comment »
The University of Pennsylvania is organizing a “first of its kind”, all-day Prostate Cancer Evidence Academy meeting in Philadelphia on November 13, 2015. Your sitemaster has been invited to coordinate a session on patient advocacy and education at that meeting. … READ MORE …
Filed under: Uncategorized | Tagged: academy, evidence, meeting, Phialdelphia | 3 Comments »
An article in the April issue of Lancet Oncology has provided additional data from the randomized, double-blind Phase III PREVAIL trial of enzalutamide versus placebo in men with asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: evidence, quality of life, survival, trials | Leave a comment »
Many readers of this news blog may want to listen to or read Dr. Gerald Chodak’s latest video blog on the Medscape Oncology web site. … READ MORE …
Filed under: Uncategorized | Tagged: evidence, opinion, patient, physician, relations, truth | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 